Stock NOVO B NOVO NORDISK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 04:35:16 2025-01-21 am EST 		5-day change 1st Jan Change
565.60 DKK +2.59% Intraday chart for Novo Nordisk A/S -5.34% -10.17%
Jan. 03 New Year, Soft Start Our Logo
Jan. 03 BNP Paribas Exane Cuts Novo Nordisk PT, Maintains at Outperform MT

Summary: Novo Nordisk A/S

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • According to MSCI, the company's ESG score for its industry is good.

Highlights: Novo Nordisk A/S

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses: Novo Nordisk A/S

  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings Chart: Novo Nordisk A/S

surperformance-ratings-chart NOVO-NORDISK-A-S
Source: Surperformance

ESG chart: Novo Nordisk A/S

esg-ratings-chart NOVO-NORDISK-A-S
Source: MSCI

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Composite Fundamentals Composite Valuation Composite Momentum Capi. ($)
NOVO NORDISK A/S Stock Novo Nordisk A/S
341B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
653B
JOHNSON & JOHNSON Stock Johnson & Johnson
354B
ABBVIE INC. Stock AbbVie Inc.
303B
MERCK & CO., INC. Stock Merck & Co., Inc.
248B
ROCHE HOLDING AG Stock Roche Holding AG
236B
ASTRAZENECA PLC Stock AstraZeneca PLC
206B
NOVARTIS AG Stock Novartis AG
197B
PFIZER, INC. Stock Pfizer, Inc.
149B
AMGEN INC. Stock Amgen Inc.
146B
Average 283.38B
Weighted average by Cap.
See all sector ratings
Investor Rating
Trading Rating
ESG MSCI
AAA

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

ESG

Environment
Social
Governance
Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. Ratings Novo Nordisk A/S